EW — Edwards Lifesciences Corporation
$107.15
+$1.35 (+1.28%)
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
Market Cap
$61.61B
Forward P/E
31.6x
52-Week Range
N/A
EW Price History
Revenue vs. Net Income
$6.1B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$1.3B
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
10.9%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
4.1x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
4.3%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-2.3%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
